Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 10/20 | 0.67 |
| ▸ | CDK7 | P50613 | 10/20 | 0.65 |
| ▸ | CDK9 | P50750 | 10/20 | 0.65 |
| ▸ | ROS1 | P08922 | 5/20 | 0.59 |
| ▸ | MET | P08581 | 5/20 | 0.59 |
| ▸ | EGFR | P00533 | 3/20 | 0.59 |
| ▸ | IGF1R | P08069 | 2/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.59 |
| ▸ | CDK4 | P11802 | 1/20 | 0.59 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.59 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.59 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | INSR | P06213 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29666260 | 1.00 | ALK (0.67) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL26617118 | 0.92 | CDK7 (0.60) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL30598344 | 0.90 | ALK (0.57) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL17879579 | 0.90 | ALK (0.56) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL1491777 | 0.89 | CDK7 (0.60) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL19912065 | 0.89 | ALK (0.66) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL18350626 | 0.89 | ALK (0.83) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL2061394 | 0.89 | ALK (0.54) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL18627479 | 0.88 | ALK (0.53) | ALKCDK7CDK9ROS1MET | |
| SCHEMBL29214361 | 0.88 | CDK7 (0.60) | ALKCDK7CDK9ROS1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114989139-A | Process for preparing pyrimidine-2, 4-diamine dihydrochloride | 诺华股份有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-111170996-B | Pyrimidine derivative with ALK inhibitory activity and synthetic method and application thereof | 天津大学 | 2021-12-28 | — | — | CN | claimed |
| CN-111171017-B | Pyrimidine-based derivatives, their preparation and use | 天津大学 | 2021-12-24 | — | — | CN | claimed |
| CN-111171033-B | Pyrimidine derivative and synthesis method and application thereof | 天津大学 | 2021-11-02 | — | — | CN | claimed |
| EP-3453708-B1 | PROCESS FOR THE PREPARATION OF 5-CHLORO-N-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N-2-(ISOPROPYLSULFONYL)PHENYL)-2,4-DIAMINE DI-HYDROCHLORIDE | NOVARTIS AG (CH) | 2021-10-27 | — | — | EP | claimed |
| CN-110143947-B | Preparation method of ceritinib analogue | 华东师范大学 | 2021-10-15 | — | — | CN | claimed |
| CN-112125884-A | Process for preparing pyrimidine-2, 4-diamine dihydrochloride | 诺华股份有限公司 | 2020-12-25 | — | — | CN | claimed |
| CN-111170996-A | Pyrimidine derivative with ALK inhibitory activity and synthetic method and application thereof | 天津大学 | 2020-05-19 | — | — | CN | claimed |
| CN-111171017-A | Pyrimidine-based derivatives, their preparation and use | 天津大学 | 2020-05-19 | — | — | CN | claimed |
| CN-111171033-A | Pyrimidine derivative and synthesis method and application thereof | 天津大学 | 2020-05-19 | — | — | CN | claimed |
| US-10604505-B2 | Modified process for the preparation of Ceritinib and amorphous form of Ceritinib | NATCO PHARMA LIMITED (IN) | 2020-03-31 | — | — | US | claimed |
| CN-106854182-B | Preparation method of 2, 5-dichloro-N- (2- (isopropylsulfonyl) phenyl) pyrimidine-4-amine | 山东轩德医药科技有限公司 | 2020-02-07 | — | — | CN | claimed |
| EP-3453708-A1 | PROCESS FOR THE PREPARATION OF 5-CHLORO-N-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N-2-(ISOPROPYLSULFONYL)PHENYL)-2,4-DIAMINE DI-HYDROCHLORIDE | Novartis AG (CH) | 2019-03-13 | — | — | EP | claimed |
| US-20190047983-A1 | MODIFIED PROCESS FOR THE PREPARATION OF CERITINIB AND AMORPHOUS FORM OF CERITINIB | NATCO PHARMA LIMITED (IN) | 2019-02-14 | — | — | US | claimed |
| WO-2017158619-A1 | A MODIFIED PROCESS FOR THE PREPARATION OF CERITINIB AND AMORPHOUS FORM OF CERITINIB | NATCO PHARMA LIMITED (IN) | 2017-09-21 | — | — | WO | claimed |
| CN-104892526-A | Preparation method of 2,5-dichloro-N-(2-isopropylsulfonyl) phenyl) pyrimidine-4-amine | 2Y CHEM LTD | 2015-09-09 | — | — | CN | claimed |
| CN-121248582-B | CDK12/PARP double-target inhibitor and preparation method and application thereof | SOUTH CHINA UNIVERSITY OF TECHNOLOGY (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-4011376-B1 | COMBINATION OF AN ALK INHIBITOR AND AN EGFR INHIBITOR FOR TREATING CANCER | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2025-04-30 | — | — | EP | disclosed |
| WO-2005016894-A1 | 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004080980-A1 | 2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604505-B2 | Modified process for the preparation of Ceritinib and amorphous form of Ceritinib | ALK, AURKA, MAP3K5 | ALK 1/4885CDK7 419/4885CDK9 388/4885 |
| US-20190047983-A1 | MODIFIED PROCESS FOR THE PREPARATION OF CERITINIB AND AMORPHOUS FORM OF CERITINIB | ALK, AURKA, MAP3K5 | ALK 1/4885CDK7 419/4885CDK9 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.